Sihuan Pharmaceutical Holdings Group (HKSE:00460) Other Financing: HK$713 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:00460 Sihuan Pharmaceutical Holdings Group Ltd HKSE:00460
79 GF Score
Price HK$0.93
GF Value HK$1.18
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sihuan Pharmaceutical Holdings Group Other Financing?

Sihuan Pharmaceutical Holdings Group HKSE:00460 +3.33% 79 Other Financing is HK$713 Mil as of Dec. 2025. GuruFocus rates HKSE:00460 with a GF Score™ of 79/100 and a GF Value™ of HK$1.18 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Sihuan Pharmaceutical Holdings Group's Other Financing for the six months ended in Dec. 2025 was HK$731 Mil.

Sihuan Pharmaceutical Holdings Group's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was HK$713 Mil.

Sihuan Pharmaceutical Holdings Group Other Financing Historical Data

* Premium members only.

The historical data trend for Sihuan Pharmaceutical Holdings Group's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sihuan Pharmaceutical Holdings Group Other Financing Chart

Sihuan Pharmaceutical Holdings Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 963.37 1,032.20 -61.04 -813.09 712.77

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -41.03 -25.10 -788.20 -17.92 730.88
HKSE:00460
79GF Score
Sihuan Pharmaceutical Holdings Group Ltd HKSE:00460
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sihuan Pharmaceutical Holdings Group Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$713 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of HK$713 Mil mean?
Sihuan Pharmaceutical Holdings Group (HKSE:00460) has a Other Financing of HK$713 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Sihuan Pharmaceutical Holdings Group and its competitors.
Is Sihuan Pharmaceutical Holdings Group's Other Financing too high?
Sihuan Pharmaceutical Holdings Group's current Other Financing is HK$713 Mil. Overall, Sihuan Pharmaceutical Holdings Group has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sihuan Pharmaceutical Holdings Group's Other Financing compare to ZTS and UTHR?
Sihuan Pharmaceutical Holdings Group's Other Financing of HK$713 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Sihuan Pharmaceutical Holdings Group and its competitors. Sihuan Pharmaceutical Holdings Group's current Other Financing is HK$713 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sihuan Pharmaceutical Holdings Group stock overvalued right now?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group (HKSE:00460) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$1.18, compared to a current price of HK$0.93 — trading 21.2% below its estimated fair value. The current Other Financing is HK$713 Mil. Sihuan Pharmaceutical Holdings Group's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Sihuan Pharmaceutical Holdings Group (HKSE:00460), the current Other Financing is HK$713 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sihuan Pharmaceutical Holdings Group (HKSE:00460) Overvalued in 2026?

Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group stock appears to be undervalued. The current stock price of HK$0.93 is trading 21.2% below its estimated GF Value™ of HK$1.18. GuruFocus considers Sihuan Pharmaceutical Holdings Group to be Modestly Undervalued.

Key valuation signals for HKSE:00460:

  • Other Financing: HK$713 Mil
  • GF Value™: HK$1.18 vs. price of HK$0.93 (21.2% below fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the HKSE:00460 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sihuan Pharmaceutical Holdings Group Business Description

Other Exchanges TEL1:Germany
Address 1 Harbour Road, Convention Plaza, Room 4905, Office Tower, Wanchai, HKG
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segment; and the generic medicine segment, which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
79GF Score

Get the complete analysis for HKSE:00460

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.93
Price
HK$1.18
GF Value